Vir Biotechnology 株価情報 (NASDAQ: VIR)

最新ニュース Vir Biotechnology (NASDAQ:VIR) 株価情報

Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Vir Biotechnology Inc

Viratech Corp

Neuralbase AI Ltd

Virco Manufacturing Corporation - Common Stock

Virco Manufacturing Corp

Viridien

Pacer Funds Trust BioThreat Strategy ETF

Virtu Financial, Inc. - Class A Common Stock

Virtu Financial Inc

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc.

Viracta Therapeutics Inc

UBS analyst Ashwani Verma maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and lowers the price target from $38 to $33.

News

Price Target

Analyst Ratings

ALKS

UBS Maintains Neutral on Alkermes, Lowers Price Target to $33

WIIM

OKTA

Okta shares are trading higher after the company announced it will replace Berry Global Group in the S&P Midcap 400, effective before the opening of trading on Thursday, May 1

<a href="https://www.bloomberg.com/news/articles/2025-04-28/alibaba-rolls-out-latest-flagship-ai-model-in-post-deepseek-race">https://www.bloomberg.com/news/articles/2025-04-28/alibaba-rolls-out-latest-flagship-ai-model-in-post-deepseek-race</a>

General

BABA

'Alibaba Rolls Out Latest Flagship AI Model in Post-DeepSeek Race'- Bloomberg

Tevogen Bio Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares are ripping higher in Monday&#8217;s after-hours session after the company reaffirmed its <a href="https://www.benzinga.com/pressreleases/25/04/g45053606/tevogen-reaffirms-oncology-top-line-revenue-forecast-of-1-billion-in-launch-year-and-cumulative-5-">oncology pipeline revenue forecast</a>.
What Happened: After the market close on Monday, Tevogen Bio reaffirmed its oncology pipeline outlook, forecasting $1 billion in revenue in its launch year. The company also projected cumulative five-year estimated sales in the range of $10 billion and $14 billion. 
&#8220;With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to updating our shareholders on our forecasts and internal assets valuation,&#8221; said Ryan Saadi, founder and CEO of Tevogen Bio.
Tevogen Bio had a market cap of approximately $173.7 million as of Monday&#8217;s close. The company is set to hold its 2025 annual meeting of stockholders on June 23.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/45053893/amkor-technology-shares-climb-after-q1-revenue-beats-q2-revenue-guidance-above-estimates">Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates</a>
<h3 class="wp-block-heading">How To Buy TVGN Stock</h3>
By now you're likely curious about how to participate in the market for Tevogen Bio — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
TVGN Price Action: <a href="http://benzinga.com/quote/tvgn">Tevogen Bio shares</a> were up 39.76% after-hours, trading at $1.31 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data.
Photo: <a href="https://www.shutterstock.com/g/Timon+photography+world">T. Schneider</a>/Shutterstock.

Biotech

Guidance

After-Hours Center

Movers

TVGN

Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On?

UBS analyst Andrew Mok maintains Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Buy and raises the price target from $117 to $130.

UBS Maintains Buy on Encompass Health, Raises Price Target to $130

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250428-1477852/1477852_bery4.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250428-1477852/1477852_bery4.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250428-1477852/1477852_bery4.pdf</a>

Markets

BERY

Okta Will Replace Berry Global Group In The S&P MidCap 400 Effective Prior To The Opening Of Trading On Thursday, May 1

UBS analyst Brian Meredith maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Neutral and raises the price target from $303 to $304.

UBS Maintains Neutral on Chubb, Raises Price Target to $304

NXPL

NextPlat  Receives Nasdaq Letter Regarding Minimum Bid Requirements

UBS analyst Brian Meredith maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Buy and raises the price target from $139 to $142.

UBS Maintains Buy on The Hartford Insurance Gr, Raises Price Target to $142

Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $29.10 million which beat the analyst consensus estimate of $28.21 million by 3.17 percent. This is a 33.36 percent increase over sales of $21.82 million the same period last year.

Earnings

Earnings Beats

EVLV

Evolv Technologies Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $29.10M Beat $28.21M Estimate

Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 50 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $27.36 million which beat the analyst consensus estimate of $26.32 million by 3.95 percent. This is a 35.51 percent increase over sales of $20.19 million the same period last year.

Evolv Technologies Q3 2024 Adj. EPS $(0.04) Beats $(0.06) Estimate, Sales $27.36M Beat $26.32M Estimate

Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBNK#NASDAQ">CBNK</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.72 by 22.22 percent. This is a 72.55 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $58.60 million which beat the analyst consensus estimate of $57.43 million by 2.03 percent. This is a 42.99 percent increase over sales of $40.98 million the same period last year.

CBNK

Capital Bancorp Q1 Adj. EPS $0.88 Beats $0.72 Estimate, Sales $58.60M Beat $57.43M Estimate

UBS analyst Myles Walton maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Neutral and raises the price target from $222 to $226.

UBS Maintains Neutral on L3Harris Technologies, Raises Price Target to $226

SunCar Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) reported $441.90 million in sales this quarter. This is a 21.49 percent increase over sales of $363.75 million the same period last year.

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SunCar Technology Group FY 2024 Revenue $441.90M Up From $363.75M YoY

UBS analyst Brian Meredith maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Buy and raises the price target from $73 to $78.

UBS Maintains Buy on WR Berkley, Raises Price Target to $78

UBS analyst Jay Sole maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and raises the price target from $56 to $59.

ONON

UBS Maintains Buy on On Holding, Raises Price Target to $59

UBS analyst Gavin Parsons maintains Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) with a Sell and raises the price target from $62 to $63.

UBS Maintains Sell on Textron, Raises Price Target to $63

SJW Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NASDAQ">SJW</a>) affirms FY2025 Adj EPS guidance from $2.90-$3.00 to $2.90-$3.00 vs $2.97 analyst estimate..

SJW Gr Affirms FY2025 Adj EPS Guidance of $2.90-$3.00 vs $2.97 Est

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is looking for Q2 Adj EPS of $0.41-$0.64 vs $0.52 analyst estimate. sees sales of $610.000 million-$680.000 million vs $643.53 million analyst estimate.

Teradyne Sees Q2 Adj EPS $0.41-$0.64 vs $0.52 Est; Sees Sales $610.000M-$680.000M vs $643.53M Est

SJW Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NYSE">SJW</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.36 by 38.89 percent. This is a 38.89 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $167.60 million which beat the analyst consensus estimate of $159.03 million by 5.39 percent. This is a 12.19 percent increase over sales of $149.38 million the same period last year.

SJW Gr Q1 Adj. EPS $0.50 Beats $0.36 Estimate, Sales $167.60M Beat $159.03M Estimate

Press Releases

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Comments

Vir Biotechnology

ニュース

最新ニュース Vir Biotechnology (NASDAQ:VIR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル